Leerink Partnrs Has Bearish Estimate for RYTM Q2 Earnings

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) - Analysts at Leerink Partnrs dropped their Q2 2025 earnings estimates for Rhythm Pharmaceuticals in a research report issued on Sunday, July 13th. Leerink Partnrs analyst F. Khurshid now anticipates that the company will post earnings per share of ($0.88) for the quarter, down from their previous estimate of ($0.86). Leerink Partnrs currently has a "Strong-Buy" rating on the stock. The consensus estimate for Rhythm Pharmaceuticals' current full-year earnings is ($4.32) per share. Leerink Partnrs also issued estimates for Rhythm Pharmaceuticals' Q3 2025 earnings at ($0.98) EPS, Q4 2025 earnings at ($1.06) EPS, FY2025 earnings at ($3.73) EPS, Q1 2026 earnings at ($0.97) EPS, Q2 2026 earnings at ($0.92) EPS, Q3 2026 earnings at ($0.80) EPS and FY2026 earnings at ($3.30) EPS.

Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.81) earnings per share for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.12). The firm had revenue of $37.72 million during the quarter, compared to analyst estimates of $40.43 million. Rhythm Pharmaceuticals had a negative net margin of 123.26% and a negative return on equity of 739.62%. The company's quarterly revenue was up 25.9% compared to the same quarter last year. During the same period in the previous year, the firm posted ($2.35) earnings per share.

A number of other equities analysts also recently commented on the stock. Wells Fargo & Company boosted their target price on shares of Rhythm Pharmaceuticals from $91.00 to $129.00 and gave the stock an "overweight" rating in a research note on Thursday, July 10th. JMP Securities reaffirmed a "market outperform" rating and set a $84.00 price objective on shares of Rhythm Pharmaceuticals in a research report on Thursday, June 26th. Guggenheim reaffirmed a "buy" rating on shares of Rhythm Pharmaceuticals in a report on Thursday, July 10th. Oppenheimer set a $110.00 price target on Rhythm Pharmaceuticals and gave the company an "outperform" rating in a report on Thursday, July 10th. Finally, Bank of America upped their target price on shares of Rhythm Pharmaceuticals from $73.00 to $95.00 and gave the company a "buy" rating in a report on Thursday, July 10th. Fourteen research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $91.00.

Rhythm Pharmaceuticals Price Performance

Shares of Rhythm Pharmaceuticals stock traded up $2.08 on Wednesday, reaching $91.44. 727,203 shares of the company were exchanged, compared to its average volume of 590,426. The stock's 50 day moving average price is $65.90 and its 200-day moving average price is $59.97. The company has a market cap of $5.82 billion, a P/E ratio of -32.54 and a beta of 2.26. Rhythm Pharmaceuticals has a 1-year low of $40.61 and a 1-year high of $94.80.

Institutional Trading of Rhythm Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BI Asset Management Fondsmaeglerselskab A S purchased a new position in Rhythm Pharmaceuticals during the 1st quarter valued at about $34,000. State of Wyoming purchased a new position in shares of Rhythm Pharmaceuticals during the 4th quarter worth approximately $61,000. GF Fund Management CO. LTD. purchased a new position in shares of Rhythm Pharmaceuticals during the 4th quarter worth approximately $72,000. CWM LLC increased its stake in shares of Rhythm Pharmaceuticals by 92.3% during the 1st quarter. CWM LLC now owns 2,584 shares of the company's stock worth $137,000 after purchasing an additional 1,240 shares in the last quarter. Finally, Bayforest Capital Ltd purchased a new position in Rhythm Pharmaceuticals during the first quarter worth $166,000.

Insider Activity

In other news, insider Alastair Garfield sold 1,319 shares of the stock in a transaction dated Wednesday, July 2nd. The shares were sold at an average price of $64.81, for a total transaction of $85,484.39. Following the completion of the sale, the insider owned 3,126 shares in the company, valued at approximately $202,596.06. This represents a 29.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Joseph Shulman sold 7,969 shares of the company's stock in a transaction that occurred on Wednesday, July 9th. The shares were sold at an average price of $77.78, for a total value of $619,828.82. Following the sale, the insider directly owned 8,509 shares of the company's stock, valued at approximately $661,830.02. This represents a 48.36% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 93,673 shares of company stock worth $7,118,510 over the last 90 days. 6.10% of the stock is owned by corporate insiders.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.